Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

Non-invasive Neurostimulation of the Vagus Nerve for the Treatment of Cluster Headache

NCT01792817 · View on ClinicalTrials.gov ↗

Study Summary

Multi-center, prospective, double-blind, randomized, sham-controlled pivotal study of non-invasive vagus nerve stimulation with the GammaCore® device for the acute treatment of cluster headache. The study compares the safety and effectiveness of an active treatment (GammaCore) against a sham treatment.

Conditions Studied

Interventions

  • DEVICE GammaCore
  • DEVICE Sham GammaCore device

Study Locations (20)

New York

  • Dent Neurologic Institute — Amherst
  • Montefiore Headache Center — New York
  • Center for Headache Care and Research at Island Neurological Associates, PC — Plainview

California

  • California Medical Clinic for Headache — Santa Monica
  • Stanford University Medical Center — Stanford

Colorado

  • Colorado Neurological Institute — Englewood

Connecticut

  • Associated Neurologists of Southern Connecticut — Fairfield

Florida

  • Tampa General Hospital Headache Center — Tampa

Illinois

  • Diamond Headache Clinic — Chicago

Iowa

  • University of Iowa Hospital and Clinics — Iowa City

Kentucky

  • Norton Neurology — Louisville

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2013-02
Est. Completion 2014-10
Phase NA

Sponsor

ElectroCore

5 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01792817

The ClinicalTrials.gov registry entry for NCT01792817 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ElectroCore, which has 5 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Cluster Headache appearing as the primary indexed condition, and to 2 interventions — of which GammaCore is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT01792817 reports 20 study locations spanning 17 distinct geographic areas — top geographies include New York, California, Colorado. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT01792817 about?

NCT01792817 is a clinical study titled "Non-invasive Neurostimulation of the Vagus Nerve for the Treatment of Cluster Headache". Multi-center, prospective, double-blind, randomized, sham-controlled pivotal study of non-invasive vagus nerve stimulation with the GammaCore® device for the acute treatment of cluster headache. The study compares the safety and effectiveness of an active treatment (GammaCore) against a sham treatme...

What is the current status of trial NCT01792817?

This trial is currently completed. It is a NA study. The enrollment target is 150 participants. The study started on 2013-02. Estimated completion is 2014-10.

What conditions does trial NCT01792817 study?

This clinical trial studies the following conditions: Cluster Headache. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT01792817?

The interventions under investigation include: GammaCore (DEVICE), Sham GammaCore device (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT01792817?

This trial is sponsored by ElectroCore, which has 5 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT01792817 being conducted?

This trial has 20 study locations across California, Colorado, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial